Fig. 3: Chemotherapy significantly affected fecal composition in a paired sub-group analysis.
From: Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
A. Alpha diversity in terms of richness in longitudinal and paired stool samples (n = 45) collected before (pre-CT, green) and after (post-CT, red) CT. B. Beta-diversity ordination plot based on principal coordinate analysis of normalized and standardized data of fecal microbiota composition in pre-CT (green) and post-CT (red) stools. Most discriminative species (C; through VIP (implemented within partial least square discriminant analysis) and pathways (D; through LEfSe) by differentiating between pre-CT and post-CT samples stools. lasma levels of metabolites through high dimensional metabolomics according to pathological lymph node involvement (no pathological lymph node involvement, pN-; pathological lymph node involvement, pN+) in terms of Glutamine (in pN- patients, n = 18, left panels; and pN+ patients, n = 16, right panels). E Ornithine (in pN- patients, n = 18, left panels; and pN+ patients, n = 16, right panels) F and Kynurenine to Tryptophan (Kyn/Trp) ratio in pN- patients monitored in patients pre-CT, (green) and post-CT, (red), n = 18 (G). P values are indicated at the top of the Y axis (Wilcoxon test).
